The Global Dry Eye Syndrome
Treatment Market is anticipated to witness an impressive growth during the
forecast period. This can be ascribed to the growing prevalence of dry eye
syndrome due to certain diseases such as rheumatoid arthritis, thyroid diseases,
and lupus across the globe. Besides, increasing drug approvals and launches of
new eye drops along with rising research and development activities in the
healthcare sector for the development of new treatments for dry eye diseases
across the globe are further expected to support the dry eye syndrome treatment
market during the forecast period. In the U.S., more than 120,000 are
blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Also,
the growing development of intranasal tear neurostimulation devices which will
increase in tear production in adults along with the development of new
treatment modalities will boost the market growth during the forecasted period.
Also, the rising number of new players in the market is anticipated to lead the
regulatory approvals and further propel the growth of the market. One of the
primary challenges facing the dry eye syndrome treatment market is a lack of
awareness among the general public about the condition and available treatment
options. Many people may not realize that their dry, itchy, or irritated eyes
are the result of dry eye syndrome or may not be aware of the range of
treatment options available to them. This lack of awareness can result in
delayed diagnosis and treatment, leading to prolonged discomfort and potential
complications. Another significant challenge facing the dry eye syndrome
treatment market is the cost of treatment. While some treatment options, such
as artificial tears, are relatively inexpensive, others, such as prescription
medications and procedures like LipiFlow, can be costly. Many insurance plans
may not cover the full cost of treatment, leaving patients with significant
out-of-pocket expenses. Like all medications and medical procedures, dry eye
syndrome treatments can have side effects. Prescription medications, in
particular, may have significant side effects, such as blurred vision, eye
irritation, and increased risk of infection. Patients must weigh the potential
benefits of treatment against the potential risks and side effects, and in some
cases, may need to try several different treatment options before finding one
that works well for them. Alternative treatments, such as home remedies and
herbal supplements, may compete with traditional dry eye syndrome treatments.
While some of these alternative treatments may provide relief for some people,
others may be ineffective or even harmful. It is important for patients to
discuss any alternative treatments they are considering with their healthcare
provider and to avoid treatments that are unproven or potentially harmful.
Growing Prevalence of Dry Eye
Disease
Most common dry eye disease is
chronic ophthalmic disorder which has high prevalence rate among aging
population compared to adults. Growing usage of screens, consuming improper
diet, growing usage of contact lenses and rising the number of LASIK surgeries
across the globe will further drive the market growth in the forecast period.
Due to increasing age, the ability of the lachrymal glands to produce tears
decreases that is leading to dry eye condition which is one of the key factors
contributing to demand for the dry eye syndrome and drive the growth of the
market during the forecasted period. Based on data from the National
Health and Wellness Survey, 6.8 percent of the United States adult population
(approximately 16.4 million people) have been diagnosed with DED. The
increasing availability of over-the-counter (OTC) treatments is another driver
of the Global Dry Eye Syndrome Treatment Market. OTC treatments such as
artificial tears and lubricating eye drops have become more readily available,
making it easier for people to manage their dry eye symptoms without the need
for a prescription. This has led to an increase in self-medication, which has
further boosted the demand for dry eye syndrome treatment. The growing
awareness and understanding of dry eye syndrome is also contributing to the
growth of the Global Dry Eye Syndrome Treatment Market. More people are
becoming aware of the condition, its symptoms, and the available treatment
options. This increased awareness is leading to earlier diagnosis and
treatment, which is improving patient outcomes and driving the overall growth
of the market. As people get older, their eyes tend to produce fewer tears.
This can lead to dry eye syndrome, particularly in women after menopause. Aging
also makes it harder for the body to produce the necessary nutrients and fluids
to maintain eye health. Environmental factors, such as air conditioning,
heating, wind, and low humidity, can cause the eyes to become dry and
irritated. Exposure to air pollution, smoke, and other irritants can also
contribute to dry eye syndrome. Many people spend a significant amount of time
in front of screens, such as computers, smartphones, and televisions. This can
cause the eyes to become strained and dry, leading to dry eye syndrome. Some
medications, such as antihistamines, decongestants, and antidepressants, can
cause dry eye syndrome as a side effect. Medical conditions, such as diabetes,
rheumatoid arthritis, and thyroid disorders, can increase the risk of
developing dry eye syndrome.
Growing investment in Healthcare
Industry
Furthermore, growing initiatives
by public and private organizations to spread awareness about new treatment of
dry eye syndrome will propel the dry eye syndrome treatment market over the
years. Changing dietary pattern and sedentary lifestyle are the factors that
will influence the market dynamics during the forecast period. Increasing the
number of eye care centres across the globe and growing penetration of OTC
eyedrop market across the developing regions will further boost the market
growth in the forecast period. In January 2022, Sun Pharma announced
the launch of dry eye treatment product named Cequa in Canada. It is the first
dry eye disease treatment that is delivered with nanomicellar (NCELL)
technology. This technology enhances the bioavailability as well as
physiochemical stability of cyclosporine to raise ocular tissue penetration. Another
key driver of the Global Dry Eye Syndrome Treatment Market is the development
of new and innovative treatment options. In recent years, there has been
significant investment in research and development, leading to the discovery of
new treatment options such as LipiFlow, a thermal pulsation system that uses
heat and massage to clear blocked oil glands in the eyelids. These new
treatment options have not only improved patient outcomes but have also
increased the overall demand for dry eye syndrome treatment. LipiFlow is a
thermal pulsation system that uses heat and massage to clear blocked oil glands
in the eyelids, which can improve tear quality and reduce dry eye symptoms. The
procedure is typically performed in a doctor's office and takes approximately
12 minutes per eye. LipiFlow is considered a safe and effective treatment for
dry eye syndrome.
Recent Development
- Cequa (cyclosporine ophthalmic solution)
0.09% was launched by Sun Pharma in 2018 as a prescription medication for
the treatment of dry eye syndrome. Cequa is a calcineurin inhibitor that
works by reducing inflammation and increasing tear production. It is the
first and only approved ophthalmic solution with a nanomicellar technology
that helps to improve drug penetration and efficacy.
- Eysuvis (loteprednol etabonate ophthalmic
suspension) 0.25% was launched by Kala Pharmaceuticals in 2020 as a
prescription medication for the short-term treatment of the signs and
symptoms of dry eye syndrome. Eysuvis is a corticosteroid that works by
reducing inflammation and improving tear production. It is the first and
only approved corticosteroid for the treatment of dry eye syndrome.
- Klarity-C (ascorbic acid 6% and
glycyrrhetinic acid 1% ophthalmic solution) was launched by ImprimisRx in
2020 as a prescription medication for the treatment of dry eye syndrome.
Klarity-C is a combination of two ingredients, ascorbic acid (vitamin C)
and glycyrrhetinic acid, that work together to reduce inflammation and
improve tear production.
- Klarity is a new over-the-counter dry eye
syndrome medication that was launched in 2021. It is a preservative-free
eye drop solution that contains hyaluronic acid, which is a naturally
occurring substance in the body that helps to retain moisture. Klarity eye
drops work by moisturizing the eyes and providing long-lasting relief from
dry eye syndrome.
Download Free Sample Report
Market Segmentation
The Global Dry Eye Syndrome
Treatment Market can be segmented by indication, product type, dosage form,
type, distribution channel and by region. Based on indication, the market can
be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye
Syndrome. Based on product type, the market can be differentiated into
Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and
Others. Based on dosage form, the market can be grouped into Gels, Eye
Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the
market can be divided into Prescription and Over the Counter. Based on
distribution channel, the market can be segmented into Hospital Pharmacies,
Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated
the market among Asia Pacific, Europe, Middle East & Africa, and South
America. Among the different countries, United States dominated the global dry
eye syndrome treatment market on account of growing demand for dry eye
treatment in the country.
Recent Development
- In 2019 October, Sun Pharmaceutical
Industries Ltd launched a product CEQUA for the treatment of dry eye
syndrome in the U.S. and the highest concentration of cyclosporine for
ophthalmic use which is approved by the U.S. FDA.
- In 2019 July, Novartis announced the
completion of the successful acquisition of Xiidra 5%, the first and only
prescription treatment approved to treat both signs and symptoms of dry
eye by controlling the inflammation caused by the disease.
Market Players
Johnson & Johnson, AbbVie
Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries
Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,
Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the
leading players operating in the Global Dry Eye Syndrome Treatment Market.
Attribute
|
Details
|
Base
Year
|
2022
|
Historic
Data
|
2018 – 2021
|
Estimated
Year
|
2023
|
Forecast
Period
|
2024 – 2028
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
Segments
Covered
|
·
By Indication
·
By Product Type
·
By Dosage Form
·
By Type
·
By Distribution Channel
·
By Region
|
Regional
scope
|
North
America; Europe; Asia Pacific; South America; Middle East & Africa
|
Country
scope
|
United States; Canada; Mexico; France; Germany; United
Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina;
Colombia; South Africa; Saudi Arabia; UAE
|
Key
companies profiled
|
Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc.,
Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical
Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon
Inc., GlaxoSmithKline plc.
|
Customization
scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
Pricing
and purchase options
|
Avail
customized purchase options to meet your exact research needs. Explore purchase options
|
Delivery
Format
|
PDF and Excel through
Email (We can also provide the editable version of the report in PPT/Word
format on special request)
|
Report Scope:
In this report, global dry eye
syndrome treatment market has been segmented into following categories, in
addition to the industry trends which have also been detailed below:
- Dry
Eye Syndrome Treatment Market, By Indication:
o Evaporative Dry Eye Syndrome
o Aqueous Deficient Dry Eye Syndrome
- Dry
Eye Syndrome Treatment Market, By Product Type:
o Cyclosporine
o Topical Corticosteroids
o Artificial Tears
o Punctal Plugs
o Others
- Dry
Eye Syndrome Treatment Market, By Dosage Form:
o Gels
o Eye Solutions
o Capsules & Tablets
o Eye Drops
o Ointments
- Dry
Eye Syndrome Treatment Market, By Type:
o Prescription
o Over The Counter
- Dry
Eye Syndrome Treatment Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
- Dry
Eye Syndrome Treatment Market, By Region:
- North
America
- United
States
- Mexico
- Canada
- Europe
- France
- Germany
- United
Kingdom
- Italy
- Spain
- Asia
Pacific
- China
- India
- Japan
- South
Korea
- Australia
- South
America
- Brazil
- Argentina
- Colombia
- Middle
East & Africa